Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Hypoxia01:23

Hypoxia

2.4K
Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
2.4K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

13.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Experimental RNAi02:15

Experimental RNAi

6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydroxychloroquine-conjugated gold nanoparticles for improved siRNA activity.

Biomaterials·2016
Same author

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.

Cancer letters·2013
Same author

Effects and mechanisms of Paeoniflorin, a bioactive glucoside from paeony root, on adjuvant arthritis in rats.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2007
Same author

Compton-scattering cross section on the proton at high momentum transfer.

Physical review letters·2007
Same author

Recoil-proton polarization in high-energy deuteron photodisintegration with circularly polarized photons.

Physical review letters·2007
Same author

Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.

International journal of laboratory hematology·2007

Related Experiment Video

Updated: May 2, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

10.1K

Hypoxia-targeted siRNA delivery.

F Perche1, S Biswas, T Wang

  • 1Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, 140 The Fenway, Room 230, 360 Huntington Avenue, Boston, MA 02115 (USA).

Angewandte Chemie (International Ed. in English)
|February 21, 2014
PubMed
Summary

Researchers developed a novel nanocarrier that effectively delivers siRNA to tumors. This hypoxia-induced gene silencing offers a promising new approach for cancer therapy, improving treatment efficacy in hypoxic tumor regions.

Keywords:
antitumor agentscancerhypoxia-triggered copolymersiRNA deliverytumor targeting

More Related Videos

siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells
10:43

siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells

Published on: May 24, 2014

10.9K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Related Experiment Videos

Last Updated: May 2, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

10.1K
siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells
10:43

siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells

Published on: May 24, 2014

10.9K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Tumor hypoxia, characterized by low oxygen levels, is a significant challenge in cancer therapy, contributing to treatment resistance.
  • Poor drug delivery to hypoxic tumor regions is a major cause of therapeutic failure.
  • Existing strategies like hypoxia imaging agents and prodrugs aim to overcome these limitations.

Purpose of the Study:

  • To demonstrate the first example of hypoxia-induced siRNA delivery and gene silencing using a novel nanocarrier.
  • To develop a tumor-environment-responsive system for targeted cancer therapy.
  • To investigate the potential of this nanocarrier for enhanced therapeutic agent delivery.

Main Methods:

  • A unique nanocarrier (PAPD) was synthesized using polyethyleneglycol, azobenzene, polyethyleneimine (PEI), and DOPE.
  • The nanocarrier's azobenzene component confers hypoxia sensitivity and specificity.
  • In vitro and in vivo experiments were conducted to assess siRNA uptake and gene silencing in hypoxic conditions and GFP-expressing tumors.

Main Results:

  • The nanocarrier successfully facilitated hypoxia-induced siRNA uptake and gene silencing in vitro.
  • Downregulation of green fluorescent protein (GFP) was observed in GFP-expressing tumors following intravenous administration of the nanocarrier.
  • The azobenzene moiety ensured specific targeting and activation in the hypoxic tumor microenvironment.

Conclusions:

  • The developed PAPD nanocarrier represents a novel platform for hypoxia-targeted siRNA delivery.
  • This approach offers a promising strategy for overcoming therapeutic resistance associated with tumor hypoxia.
  • The nanoformulation demonstrates potential as a tumor-environment-responsive modality for advanced cancer treatment.